Clinical Trials Logo

Clinical Trial Summary

Patients who self-harm are a heterogeneous population. Outpatient treatments structured for borderline personality disorder are often recommended and hospitalization kept to a minimum. However, few studies have focused on the most severe, complex conditions with extreme suicide risk. A recent national investigation from Norway (2017) demonstrated a far larger cohort of extensively hospitalized inpatients with extreme self-harming behaviors than was expected (N=427) - identified in all health regions. Reported challenges were high-risk situations, severe medical sequelae, difficult collaborations across services, and uncertainty about psychiatric diagnoses. Severe, often bizarre, self-harm is thus a major challenge for both patients and health services. In hospitals, safety measures can involve restrictions and involuntary regimes. As research on this target population is sparse, the current project seeks further understanding of complex conditions - psychopathology, treatment experiences and service collaboration. The project is a national, multi-center cooperation including patients in psychiatric hospitals in all health regions. It is cross sectional. Data is based on diagnostic interviews, patients' self-reported symptoms and both patients and service providers treatment experiences. The inclusion period for inpatients (N=300) and a comparison sample of outpatients (N=300) is one year. The target group is inpatients with extreme hospitalization and severe self-mutilation. A comparison group is patients with personality pathology attending outpatient treatments. Recruitment is across health regions. Aim 1: Investigate psychopathology of patients in the target population and compare to a clinical sample admitted to outpatient treatment Aim 2: Investigate personality functioning in the target population and compare to a clinical sample admitted to outpatient treatment Aim 3: a) Investigate health service use in the target population and compare to a clinical sample admitted to outpatient treatment. b) Investigate treatment experiences and health service collaborations in the target population. The project will provide rational for future preventive treatment interventions


Clinical Trial Description

Design: A cross-sectional investigation. The inclusion period will be one year. The target group: Patients admitted to inpatient units (adult psychiatry, mental health centres or hospitals) due to risk of severe self-harm. The duration of admissions are either more than 4 weeks and/or patients have had more than five admissions in the preceding year. The comparison group is a collaboration with the Norwegian Network of personality-focused treatments and includes clinical data from 19 outpatient units within specialist mental health services across Norway (baseline data for 300 patients admitted to treatment during 2017-2018). Sample size: An inclusion of N=300 patients in the target Group and comparison group Assessments: The assessment battery combines therapist administered interviews and patient self-report measures to provide a broad differential-diagnostic evaluation and information about treatment and health-service collaborations. It also includes therapist-reports. Psychopathology: Assessment of psychiatric disorders includes interviews for symptom disorders (MINI), personality traits and disorders (SCID-5-PD, and observer-evaluated global functioning (GAF) administered in both the target and the comparison group. Assessment of the target group will additionally include a screening interview on cognitive functioning (Hayes Ability Screening Index, HASI, specific approval has been given), self-report screening of autism (Ritvo Autisme Asperger Diagnoseskjema - Revidert RAADS-R), and a detailed interview on psychosis (questions from MINI plus). General, social and personality functioning: The assessment battery includes a combination of well-established, (no cost) self-report measures covering overall functioning, symptoms, trauma, personality functioning and maladaptive behaviors. These will be administered in both the target and the comparison group. More details on assessment battery can be given on request to PI. Self-harming behaviors: Self-report on self-harming behaviors and suicide attempts last 6 months are included. Assessment of the target group will additionally include a more detailed interview of self-harming behaviors adapted for Norwegian studies (Lifetime Para suicide Count). Service use, treatment experiences, and health service collaborations: Assessment of previous treatments, age first time, and contact with child/adolescent psychiatry (self-report, both the target and the comparison group), and a detailed interview on medication, treatments, primary health care and welfare services last 6 months (specially designed interview, both target and comparison group). In addition, for the target group, questions about involuntary and restrictive regimes, treatment involvement, confidence, alliance and collaboration within and across health services are included (patient and therapist reported). Research collaborators: The PhD candidate will follow the PhD educationary program at the University of Oslo. Main supervisor is also Principle Investigator (E.H.Kvarstein), and co supervisor (G.Pedersen) heads the Network collaboration. The PhD candidate will join the national project group and be an associated member of the Research group for Personality Psychiatry. The national project group is central in all phases; design, preparations, implementation procedures, evaluation, and presentations of results. It covers all health regions, relevant research environments, clinicians and users. It includes: Middle HR: T.Torgersen, PhD, Western HR: T.Tveit, MD. Southeastern HR: P.A.Ringen, PhD, P.Danielsen, MA, C.A.Sveen (MA), Tore Buer (MD). Northern HR: H.Tvete, MD, T.Høifødt, PhD. National Centre, Suicide Research and Prevention: F.Walby,MA, R.K.Ramleth, MD (BUP). Regional Centre, Violence and Traumatic Stress: I.Lunde, MA. Early intervention Psychosis: K.L.Romm, PhD. Personality Psychiatry National Advisory Unit: Ø.Urnes,MD. User experience: T.Røstbakken, M.Pettersen, A.Holst. The Research group for personality psychiatry (University of Oslo/Oslo University Hospital) is an active, well-established research group with engagement in national and international research collaborations specializing on personality pathology and clinical research. The principle investigator (PI) and main supervisor of this project, E.H.Kvarstein, associate professor, University of Oslo/ Head senior consultant, Section for Personality Psychiatry, Oslo University Hospital, is head of the Research group of personality psychiatry. The Norwegian Network for personality-focused treatment is a well-established collaboration aiming to ensure clinical quality, systematic treatment evaluation and generate data for clinical research (anonymous data collection). The Network was established in 1993 and currently includes 19 outpatient treatment teams across Norway for patients with personality disorder. Approximately 400 patients are admitted to treatments within the Network each year (mean treatment duration: 2 years). The Network provides systems for patient assessment and progress evaluation, systematic feedback reports on clinical outcomes and supervision/seminars on diagnostic assessment and treatment. The main (ongoing) research project in the Network is a multi-centre feasibility investigation of evidence-based treatment for personality disorder (started in 2017) aiming to include longitudinal treatment data for 500 patients. "Extreme challenges" is a research collaboration between the national project group and the Network. Baseline data from the multi-centre project constitute the outpatient comparison group in "Extreme challenges" (300 patients, admitted to outpatient treatment in 2017-18, data available in 2020). Cosupervisor in the PhD project, head of the Network, is senior researcher Geir Pedersen. He is affiliated within the Section for Personality Psychiatry, Oslo University Hospital and the University of Oslo. He is a member of the research group. Norwegian National Advisory Unit on Personality Psychiatry (NAPP) is the initiator of the current project and the organizer of the national project group. With the establishment of an expert user panel (recruiting users from the whole country), NAPP has also had an active role establishing user engagement in this project. Plan for activities - practical implementation of the cross sectional investigation: The national project group has already completed a preliminary screening investigation, first publication, and designed the current project. The project group is currently preparing practical implementation of the project (mobilizing regional collaborators, local resource groups and finalizing ethic approvals and systems for data collection). 2018/19: Preparation: Regional preparatory seminars for local clinicians and all collaborators are scheduled to autumn 2019. 2019/2020: Data collection: Assessments of the target population will be performed at the inpatient institutions by local clinicians qualified for diagnostic procedures. During the data collection possibilities for feedbacks/clinical discussion of individual cases will be offered. Assessments in the comparison group involve measures already implemented (from June 2017). 2021: Dataanalysis, discussion and presentation of results: Datacollection will be concluded and analyses of results proceeds. 2022: Project conclusion Plan for dissemination of results: Running information about the project with Norwegian summaries, key researchers and references to all publications will be available at the internet home site of the Research group for Personality Psychiatry in all phases of the project. Three research publications are scheduled. Manuscripts will be submitted to international peer reviewed journals (open access publication). Research results will also be presented in relevant international/national conferences When the project is concluded, the project group will arrange a conference for participating clinicians/institutions/organizations, evaluating the investigation, implications and further developments. User involvement: The project-group includes three members with relevant user experience, Thea Røstbakken, Mona Pettersen and Andrea Holst. Ethical considerations The regional ethical committee (REC) has approved the investigator's application for ethical approval. REC reference number is: 2018/1124 A (REC South East). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03768674
Study type Observational
Source Oslo University Hospital
Contact
Status Completed
Phase
Start date October 1, 2019
Completion date September 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Recruiting NCT04356924 - Psychological Treatment to Support the Consequences of Cognitive Impairment N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Terminated NCT04493957 - Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT04426838 - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad N/A
Completed NCT04713384 - Remote Bimanual Virtual Rehabilitation Post CVD N/A
Recruiting NCT06284213 - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting NCT06053775 - Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP) N/A
Completed NCT03698695 - A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers Phase 1
Not yet recruiting NCT05552729 - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Phase 1/Phase 2
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT03187353 - IMProving Executive Function Study Phase 4
Completed NCT03301402 - Air Purifier to Improve Endothelial Function and Carotid Intima Thickness N/A
Completed NCT05395559 - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Recruiting NCT04907565 - Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Recruiting NCT05030285 - Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment N/A